GFAP and Parkinson disease: Among plasma markers including GFAP, p-tau181, amyloid-β 1–40, and amyloid-β 1–42, plasma NfL demonstrated superior performance in distinguishing PSP from healthy controls and PD, though not from MSA-P (AUC 0.624) [53].